This is a paid press release. Contact the press release distributor directly with any inquiries.

Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

Pharming Group N.V.

Thu, February 26, 2026 at 4:00 PM GMT+9 2 min read

In this article:

PHAR

+0.30%

Pharming Group N.V.

**Leiden, the Netherlands, February 26, 2026: **Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026.

Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT.

To participate in the conference call or to watch the live webcast, please register in advance using the links below.

Conference call registration:
**

Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

_Please note, the Company will only take questions from dial-in attendees. _

**Webcast registration: **
**

The webcast will also be accessible on the Pharming website at Investors/Financial Documents, and a replay will be available shortly after the event.

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: media.relations@pharming.com

U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

Pharming Group to report 4Q25_FY25 results_EN_26FEB26

Terms and Privacy Policy

Privacy Dashboard

More Info